Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
UMC Utrecht
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Natera, Inc.
Novartis
Var2 Pharmaceuticals
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
A2 Biotherapeutics Inc.
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Columbia University
Tempus AI
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Taproot Health
Washington University School of Medicine
Corvus Pharmaceuticals, Inc.
Sunnybrook Health Sciences Centre
Charite University, Berlin, Germany
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Institut de Cancérologie de Lorraine
Abramson Cancer Center at Penn Medicine
MacroGenics
Institut Bergonié
SpeciCare
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
National Cancer Institute (NCI)
University Hospital Tuebingen
Stanford University
Instituto do Cancer do Estado de São Paulo
CureOne
Novartis
Stanford University
Mayo Clinic
Stanford University
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Siemens Molecular Imaging